Skip to main content

Month: June 2022

Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress

AFM13 monotherapy: Completed enrollment in the REDIRECT study for patients with relapsed or refractory PTCL; on track to report topline data in the fourth quarter of 2022 AFM13 combination with NK cells: Reported data at AACR 2022 showing a 100% objective response rate (ORR) and an increase in complete responses (CR) from 38%, reported in December, to 62% after a second cycle of therapy in 13 patients at the recommended phase 2 dose (RP2D) with encouraging signals on durability AFM24 monotherapy: Completed enrollment of the 720mg cohort; presented data at AACR 2022 and NK2022; data show a plateau in NK cell activation and CD16 receptor binding and confirm 480mg as the RP2D AFM24 combination studies with NK cells and anti PD-L1 checkpoint inhibitor: Continued enrollment of patients in two separate phase 1/2a studies investigating AFM24...

Continue reading

Roper Technologies To Sell Majority Stake In Its Industrial Businesses To CD&R

SARASOTA, Fla., June 01, 2022 (GLOBE NEWSWIRE) — Roper Technologies, Inc. (NYSE: ROP) today announced that it has agreed to sell a majority stake in its industrial businesses, including its entire Process Technologies segment and the industrial businesses within its Measurement & Analytical Solutions segment, to affiliates of Clayton, Dubilier & Rice, LLC (“CD&R”). Roper will receive total upfront, pre-tax cash proceeds of approximately $2.6 billion while retaining a 49% minority interest in a new standalone entity. The transaction includes the following businesses: Alpha, AMOT, CCC, Cornell, Dynisco, FTI, Hansen, Hardy, Logitech, Metrix, PAC, Roper Pump, Struers, Technolog, Uson, and Viatran. Collectively, these businesses generated approximately $940 million of revenue and $260 million of EBITDA in 2021. “This...

Continue reading

vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare

HIGH POINT, N.C., June 01, 2022 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd (“G42 Investments”). Under the terms of the agreements, G42 Investments acquired 10,386,274 shares of Class A Common Stock of vTv at an issue price of $2.407 per share, with $12.5 million paid in cash at closing, and the remaining amount of $12.5 million payable on May 31, 2023. The agreements also provide for the potential issuance of $30 million in additional shares of Class A Common Stock to G42 Investments (or cash in lieu of such issuance at the option of G42 Investments) if the United States Food and Drug Administration (the “FDA”) approves the marketing and sale of a pharmaceutical product containing TTP399, a liver selective...

Continue reading

Karen Krause Joins TransUnion as Chief Strategy and Communications Officer

Accomplished executive brings deep expertise leading global strategy and corporate development CHICAGO, June 01, 2022 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) has hired Karen Krause as Executive Vice President, Chief Strategy and Communications Officer, effective June 1. Karen brings deep strategy and corporate development expertise in financial services with extensive experience in growing businesses through acquisitions and transforming operations to grow capabilities globally. She will be responsible for leading TransUnion’s Global Strategy, Communications and Branding functions, with a focus on enabling, facilitating and monitoring our transformation across global platforms and products to achieve our vision and strategy. She will partner with Finance and the Business to support our growth in relation to future M&A priorities. “TransUnion...

Continue reading

Eagle Pharmaceuticals Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, a Beta-1 Adrenergic Blocker

— Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter — — Expected approval mid-year 2023, if accepted by FDA for filing, based on feedback from U.S. Food and Drug Administration (“FDA”) provided during AOP Health’s Type C meeting — — Enrollment of study of pediatric patients with supraventricular tachycardia is underway in Europe and is designed to serve as the basis for proposed pediatric study plans for a future FDA submission — — If landiolol is approved, Eagle expects five years of new chemical entity exclusivity — WOODCLIFF LAKE, N.J., June 01, 2022 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced...

Continue reading

With 9.4% CAGR, Pain Management Devices Market Size worth USD 8,046.3 Million in 2026

According to Fortune Business Insights, The Pain Management Devices Market was valued at US$ 3,922.9 Mn in 2018. market will reach US$ 8,046.3 Mn by 2026, exhibiting a CAGR of 9.4%. Growing Adoption of Pain Management Devices to Favor Growth of Market in North America Pune, India, June 01, 2022 (GLOBE NEWSWIRE) — The global pain management devices market will benefit from increasing regulatory approvals for neuromodulation devices in recent years. According to a report published by Fortune Business Insights, titled “Pain Management Devices: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 3,922.9 Mn in 2018. Fortune Business Insights states that the market will reach US$ 8,046.3 Mn by 2026, exhibiting a CAGR of 9.4%. Pain management devices aid in reducing chronic pain and other undesirable...

Continue reading

With 6.3% CAGR, Animal Health Market Size worth USD 67.56 Billion in 2026

According to Fortune Business Insights, The global animal health market size is anticipated to reach USD 67.56 billion by 2026, the market size was USD 41.50 billion in 2018 and is anticipated to rise at a CAGR of 6.3%. Increasing Number of Pet Owners and Emphasis on Animal Health to Propel Growth Pune, India, June 01, 2022 (GLOBE NEWSWIRE) — The global animal health market size is anticipated to reach USD 67.56 billion by 2026 owing to the increasing number of animal health issues worldwide. Animals have always been of immense help to man either as companions or as livestock. With time, man starting adopting animals and keeping them as pets. Animals, alike humans, are susceptible to infections and diseases and require medical aid. As per a recently published report by Fortune Business insights™ titled, “Animal Health Market Size,...

Continue reading

Rainwater Harvesting Market Size [2022-2029] | Industry Trends, Growth, Share, Companies, Demand, And Global Forecast Analysis

Rainwater Harvesting Market Companies Studied in this Report Are Rainwater Harvesting Ltd, FILTRACON, Watts Water Technologies, Heritage Water Tanks, Water Field Technologies Pvt. Ltd., Innovative Water Solutions LLC, Kingspan, Graf UK Ltd, Harvest Rain, Water Field Technologies Pvt. Ltd., Rainwater Connection, Tosca Tech Rain Water Harvesting System, B.S. Rain Harvesting Co., Ashwath Infratech, Pune, India, June 01, 2022 (GLOBE NEWSWIRE) — The global rainwater harvesting market size is expected to experience substantial growth backed by the growing demand for rainwater harvesting plants from residential and commercial complexes and the increasing awareness regarding depleting freshwater resources worldwide. This information is published by Fortune Business Insights in its upcoming report, titled, “Rainwater Harvesting Market,...

Continue reading

China Index Holdings Receives Notification from Nasdaq Regarding Minimum Bid Price Requirements

BEIJING, June 01, 2022 (GLOBE NEWSWIRE) — China Index Holdings Limited (NASDAQ: CIH), (“CIH” or the “Company”), a leading real estate information and analytics service platform provider in China, today announced that the Company has received a written notification from Nasdaq Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) dated May 31, 2022. The letter states that the Company is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5450(a)(1) (the “Rule”), because the bid price of the Company’s American depositary shares (“ADSs”) closed below US$1 per share for the 30 consecutive business days from April 18 through May 27, 2022. The Company is granted a compliance period of 180 calendar days, expiring on November 28, 2022, to regain compliance. The Company...

Continue reading

Lands’ End and Draper James Release Final Collection for Summer 2022

Lands’ End X Draper James Lands’ End X Draper James Summer 2022 CollectionBrand’s limited-edition line with Reese Witherspoon sunsets with playful seasonal looks for the whole family DODGEVILLE, Wis., June 01, 2022 (GLOBE NEWSWIRE) — Lands’ End (NASDAQ: LE), a classic American lifestyle brand known for high quality apparel for the whole family and the home, and Draper James, a brand founded by Reese Witherspoon and inspired by her Southern roots, today announce the fourth and final collection of their two-year partnership. Building on the success of the collaboration’s past several seasons, the latest line will pair Lands’ End’s classic silhouettes with Draper James’ iconic gingham and floral prints across women’s, men’s and children’s apparel and swimwear. In line with Lands’ End’s emphasis on celebrating every...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.